PG
Procter & Gamble Health Limited
PGHL.NS · NSE
₹5,400.00 -0.47% (-₹25.50)
1M -7.28%
Market Cap ₹90.2B
P/E Ratio 35.92x
Div. Yield -
ROE 45.55%
Bulios Fair Price
₹4,933
8.7% downside
Current Price
₹5,400
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PGHL.NS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
13 /100
Expensive P/E 35.92x
EV/EBITDA 24.42x
P/S 7.41x
Growth
44 /100
Stable EPS growth 9.22%
Rev. growth 3.01%
FCF growth 8.33%
Profitability
95 /100
Strong Gross margin 71.35%
Net margin 20.62%
Op. margin 51.98%
Quality
100 /100
Excellent ROIC 81.75%
ROE 45.55%
ROA 31.63%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 2.44x
Int. coverage 598.43x
Stability
71 /100
Stable Beta 0.20x
Rev. volatility 8.64%
EPS volatility 20.00%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PGHL.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Milind Vasant Thatte
Employees
1,336
Headquarters
Mumbai
Upcoming events
02 DEC
Earnings
Upcoming earnings report